<DOC>
	<DOC>NCT02326740</DOC>
	<brief_summary>The study will evaluate the efficacy and safety of gevokizumab in treating active ulcers of pyoderma gangrenosum (PG).</brief_summary>
	<brief_title>An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum</brief_title>
	<detailed_description />
	<mesh_term>Pyoderma Gangrenosum</mesh_term>
	<mesh_term>Pyoderma</mesh_term>
	<criteria>A clinical diagnosis of classic pyoderma gangrenosum An active pyoderma gangrenosum ulcer Contraceptive measures adequate to prevent pregnancy during the study Clinical evidence of acutely infected pyoderma gangrenosum History of allergic or anaphylactic reactions to monoclonal antibodies History of recurrent or chronic systemic infections Female subjects who are pregnant, planning to become pregnant, have recently delivered, or are breastfeeding Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Pyoderma Gangrenosum</keyword>
	<keyword>Classic Pyoderma Gangrenosum</keyword>
</DOC>